Patent ID: 8492105
Filing Date: 2013-07-23
Classification: A61K,A61P,C07K,C12Q,G01N

Abstract:
1. A screening method for at least one of an insulin resistance improving agent and a therapeutic agent for diabetes, the screening method comprising: determining the presence or absence of interaction between signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase 2 (ERK2) to select a compound having a phosphorylation inhibitory activity, and evaluating the compound for whether X>Y where X denotes a Homeostasis model assessment-Insulin Resistance (HOMA-IR) value of a diabetes model animal to which the compound has not been administered and Y denotes a HOMA-IR value of a diabetes model animal to which the compound has been administered, wherein the determining is performed by preparing a mixture by mixing together at least the compound, the STAT3 whose Ser727 is not phosphorylated, and an enzyme that phosphorylates the STAT3; reacting the STAT3 whose Ser727 has been phosphorylated in the mixture with an antibody that binds to a phosphorylated site of the STAT3 whose Ser727 has been phosphorylated; and screening for the compound present in the mixture containing the STAT3 to which the antibody has not bound, as a compound having the phosphorylation inhibitory activity.